Exhibit 99.1 LOGO Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights. "We are pleased by strong top-line revenue growth of PEMGARDA® (pemivibart), which we believe is attributable to our commercial execution and the fundamental appeal of monoclonal antibody prophylaxis even in the face of declining COVID vac ...